TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05388448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sanfetrinem Cilexetil
Description: Sanfetrinem cilexetil powder, weighed for dose and administered as a suspension in water.~Amx/CA 250/125 mg tablets Rifampicin 150 mg, 300 mg and 600 mg tablets or capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sanfetrinem Cilexetil
Description: Sanfetrinem cilexetil powder, weighed for dose and administered as a suspension in water.~Amx/CA 250/125 mg tablets Rifampicin 150 mg, 300 mg and 600 mg tablets or capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sanfetrinem Cilexetil
Description: Sanfetrinem cilexetil powder, weighed for dose and administered as a suspension in water.~Amx/CA 250/125 mg tablets Rifampicin 150 mg, 300 mg and 600 mg tablets or capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sanfetrinem Cilexetil
Description: Sanfetrinem cilexetil powder, weighed for dose and administered as a suspension in water.~Amx/CA 250/125 mg tablets Rifampicin 150 mg, 300 mg and 600 mg tablets or capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sanfetrinem Cilexetil
Description: Sanfetrinem cilexetil powder, weighed for dose and administered as a suspension in water.~Amx/CA 250/125 mg tablets Rifampicin 150 mg, 300 mg and 600 mg tablets or capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sanfetrinem Cilexetil
Description: Sanfetrinem cilexetil powder, weighed for dose and administered as a suspension in water.~Amx/CA 250/125 mg tablets Rifampicin 150 mg, 300 mg and 600 mg tablets or capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanic acid
Description: Amx/CA will be administered orally as Amx/CA 250/125 mg, 1 tablet twice daily for 14 days alongside with sanfetrinem cilexetil.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Rifampicin will be administered at a dose of 35 mg/kg once daily for 14 days with or without sanfetrinem cilexetil.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Rifampicin will be administered at a dose of 35 mg/kg once daily for 14 days with or without sanfetrinem cilexetil.
Study: NCT04992338

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile app
Description: The CarpeDiem application is a mobile application, designed in collaboration with the Health and Nutrition Technology Unit (UTNS, Eurecat) and the translational research group on respiratory medicine of the Institut de Recerca Biomèdica de Lleida. The application is available for devices with Android as the operative system and its advanced interface allows the user to monitor their physical activity, sleep and diet and motivate them to meet personalized goals through gamification. To do this, the user must answer the questionnaires that they will find on the main page of the application with a predetermined frequency, as well as perform missions that will help them acquire healthier habits. In addition, the user will receive motivational messages and recommendations through notifications that will help and guide them to achieve their missions and achieve their goals, and as a result of changing habits.
Study: NCT04477317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4% Articaine Hydrochloride with 1:100,000 Adrenaline
Description: new Egyptian articane anesthetic solution.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2% Mepivacaine Hydrochloride with 1:20,000 Levonordefrin
Description: Mepecaine-L is the brand name of the Egyptian 2% Mepivacaine. It is the most commonly used anesthetic solution in Egypt due to its availability and its lower cost.
Study: NCT05741775

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic training
Description: The warm-up exercise will include light aerobic activity and some dynamic stretching movements. Similarly, the cool down exercises will include buttock stretch, hamstring stretch, inner thigh stretch, calf stretch and thigh stretch. Each stretch to be performed for 5 repetitions with a hold time of 15 seconds for each. An elastic band secured around the head will be used to apply local pressure over the area. Kettler Computeranleitung Advanced display will be used to train static cycling. ProAction BH Treadmill G6700 instrument will be used for aerobic training.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biofeedback Training
Description: Neurotrac myoplus 4 pro instrument will be used for EMG biofeedback training.
Study: NCT05474573

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Combined ultrasound and fluorescence-guided brain tumor resection
Description: Surgeon intraoperatively assesses extent of tumor resection observing it's fluorescence in microscope and performing sonography

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fluorescence-guided brain tumor resection
Description: Surgeon intraoperatively assesses extent of tumor resection observing it's fluorescence in microscope
Study: NCT05541081

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Point-of-care STI testing
Description: Testing for:~* Chlamydia and gonorrhoea using the GeneXpert platform (Cepheid)~* Trichomoniasis using the OSOM Trichomonas Rapid Test (Sekisui Diagnostics)~* HIV and syphilis using the SD BIOLINE HIV/Syphilis Duo (Abbott Diagnostics Medical Co. Ltd)~* Hepatitis B using the HBsAg2 rapid test (Abbott Diagnostics Medical Co. Ltd)
Study: NCT06270576

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lipopolysaccharides
Description: LPS aka endotoxin is a component of bacterial cell walls and is ubiquitous in the environment. It is found in pet dander, house dust and environmental dusts and has been heavily studied in asthma.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lipopolysaccharides
Description: LPS aka endotoxin is a component of bacterial cell walls and is ubiquitous in the environment. It is found in pet dander, house dust and environmental dusts and has been heavily studied in asthma.
Study: NCT04816162

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketofol
Description: prepared in a ratio of (1:4) respectively), where 1ml of ketamine will be added to 20 ml of propofol in a syringe pump

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine
Description: 2 ml (200 µg) of dexmedetomidine added to 0.9% normal saline in a syringe pump

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: normal saline 0.9% in a syringe pump
Study: NCT04959006

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Antioxidant supplement
Description: Short term (16d) supplementation of either the antioxidant supplement (Oliphenolia) or placebo. Participants required to consume 2x25ml drinks, one mid-morning, one mid-afternoon between meals.
Study: NCT06127342

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate Intensity Exercise
Description: Participants will wear a heartrate monitor and cycle on a stationary bike at a slow speed for 5 minutes, then slowly cycle on a stationary bike for 30 minutes, then cycle on the stationary bike at a slow speed for 5 minutes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low Intensity Exercise
Description: Participants will wear a heartrate monitor and cycle on a stationary bike at a slow speed for 40 minutes.
Study: NCT06574451

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VR-assisted postoperative analgesia
Description: Patients will receive postoperative analgesic adjunctive therapy software to assist in pain control, with one postoperative analgesic adjunctive therapy software intervention at 24 hours and 48 hours after surgery, and pain evaluation within 30 minutes.
Study: NCT06575322

Intervention type: DRUG
Intervention: Carboplatin（ neoadjuvant）
Description: Carboplatin (IV), AUC=5，administered by intravenous (IV) infusion on Day 1 of each 21-day cycle

Intervention type: DRUG
Intervention: Paclitaxel （neoadjuvant）
Description: Nab-paclitaxel 260mg/m2 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle

Intervention type: DRUG
Intervention: Anti-PD-1 Drugs
Description: Anti-PD-1 Drugs 200 mg administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
Study: NCT04959006

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06575322

Intervention type: PROCEDURE
Intervention: Surgical resection
Description: Standard of care

Intervention type: PROCEDURE
Intervention: Surgical resection
Description: Standard of care
Study: NCT05112081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: The group will receive a solution of 100 units BTX with 10 ml sterile saline close to the superficial inguinal ring.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sterile saline
Description: The group will receive a solution of 10 ml sterile saline close to the superficial inguinal ring.
Study: NCT05002634

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: undenatured collagen type II (UCII) supplement
Description: The undenatured collagen type II (UCII) supplement 40 mg will be taken once daily for 2 months.
Study: NCT05439096

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Exercise
Description: Among Functional Exercises, cobra position is most effective in reducing pelvic pain while others are cat and fish position.Kegel exercises along with other strengthening activities for pelvic floor muscles have been accounted for in writing to favorably affect primary dysmenorrheal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Frequency Transcutaneous Electrical Nerve Stimulation
Description: Transcutaneous electrical nerve stimulation, best treat primary dysmenorrhea. Transcutaneous Electrical Nerve Stimulation is proposed as an incredible spasm decrease, lessening torment, decline of analgesics and improving personal satisfaction in primary dysmenorrhea patients.
Study: NCT05098652

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CuRB-IT
Description: 9 1-hour coaching sessions delivered over a videoconferencing platform (Zoom); 6 delivered weekly, 3 delivered biweekly

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CuRB-IT
Description: 9 1-hour coaching sessions delivered over a videoconferencing platform (Zoom); 6 delivered weekly, 3 delivered biweekly
Study: NCT05005507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-73763989
Description: JNJ-73763989 will be administered subcutaneously once every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-73763989
Description: JNJ-73763989 will be administered subcutaneously once every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-73763989
Description: JNJ-73763989 will be administered subcutaneously once every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PegIFN-alpha-2a
Description: PegIFN-alpha-2a will be administered subcutaneously once weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PegIFN-alpha-2a
Description: PegIFN-alpha-2a will be administered subcutaneously once weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PegIFN-alpha-2a
Description: PegIFN-alpha-2a will be administered subcutaneously once weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil
Description: Tenofovir disoproxil film-coated tablet will be administered orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil
Description: Tenofovir disoproxil film-coated tablet will be administered orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil
Description: Tenofovir disoproxil film-coated tablet will be administered orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAF
Description: TAF film-coated tablet will be administered orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAF
Description: TAF film-coated tablet will be administered orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAF
Description: TAF film-coated tablet will be administered orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETV
Description: ETV film-coated tablet will be administered orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETV
Description: ETV film-coated tablet will be administered orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETV
Description: ETV film-coated tablet will be administered orally once daily.
Study: NCT04811872

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intact umbilical cord milking (I-UCM)
Description: Umblical cord milking will be performed by holding the newborn at or ∼20 cm below the level of the placenta. The cord will be pinched between 2 fingers as close to the placenta as possible and milked toward the infant over a 2-second duration. The cord will then be released and allowed to refill with blood for a brief 1- to 2-second pause between each milking motion. This will be repeated for 2-4 times. After completion, the cord will be clamped, and the neonate will be handed to the resuscitation team.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cut-umbilical cord milking(C-UCM)
Description: This technique involves clamping and cutting a long segment of the umbilical cord immediately at birth and passing the baby and the long cord to the pediatric provider, called C-UCM untwists the cord and milks the entire contents into the baby. Milking the cord 2-3 times before clamping may produce a similar placental transfusion as C-UCM.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Delayed Cord Clamping (DCC)
Description: Infants placed on the maternal abdomen or at the introitus below the level of placenta and waiting at least 30- to 60 seconds before clamping the cord.
Study: NCT05584956

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L_carnitine
Description: l-carnitine stabilizes red blood cell membranes and thus improves the anemic state\[

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: selective and potent inhibitor of cGMP-specific phosphodiesterase 5 (PDE5), which promotes smooth muscle relaxation in lung vasculature, has been used successfully in the treatment of primary and secondary PH.
Study: NCT06476990

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy food box
Description: All participants received 12 weekly deliveries of food containing approximately $8 worth of shelf-stable food items purchased from a local food bank (beans, canned vegetables and no-sugar added fruit, shelf-stable dairy products, canned tuna, and whole grains) and $25 of fresh produce (5-7 items including leafy greens, peppers, potatoes, broccoli, carrots, zucchini, cauliflower, celery, cabbage, asparagus, apples, or strawberries). When seasonably available, fresh vegetables and fruit were sourced from local farmers via a local food hub. In addition to food, participants in the Food + CHW group also received 7 weekly virtual sessions with a CHW (four 90-minute ZOOM counseling sessions and three 30 to 60-minute check-in phone calls). CHW sessions included diabetes-appropriate cooking and nutrition education and personalized benefit enrollment and linkage to existing food access resources (for example SNAP, Double up Food Bucks, and Kansas Senior Farmers Market Vouchers).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy food box
Description: All participants received 12 weekly deliveries of food containing approximately $8 worth of shelf-stable food items purchased from a local food bank (beans, canned vegetables and no-sugar added fruit, shelf-stable dairy products, canned tuna, and whole grains) and $25 of fresh produce (5-7 items including leafy greens, peppers, potatoes, broccoli, carrots, zucchini, cauliflower, celery, cabbage, asparagus, apples, or strawberries). When seasonably available, fresh vegetables and fruit were sourced from local farmers via a local food hub. In addition to food, participants in the Food + CHW group also received 7 weekly virtual sessions with a CHW (four 90-minute ZOOM counseling sessions and three 30 to 60-minute check-in phone calls). CHW sessions included diabetes-appropriate cooking and nutrition education and personalized benefit enrollment and linkage to existing food access resources (for example SNAP, Double up Food Bucks, and Kansas Senior Farmers Market Vouchers).
Study: NCT06283329

Intervention type: DIAGNOSTIC_TEST
Intervention: vocal cords echography
Description: Ultrasound assessments of the amplitude of the vocal cords movement were performed on a sagittal median section of the arytenoid cartilages with a 30° inclination using a Golf Head ultrasound probe at 3 different time points: before induction (T0), after extubation (T1), in recovery room 30 minutes after extubation(T2). We have defined H0, H1 and H2, the maximum course of the vocal cords measured respectively at T0, T1 and T2

Intervention type: DIAGNOSTIC_TEST
Intervention: vocal cords echography
Description: Ultrasound assessments of the amplitude of the vocal cords movement were performed on a sagittal median section of the arytenoid cartilages with a 30° inclination using a Golf Head ultrasound probe at 3 different time points: before induction (T0), after extubation (T1), in recovery room 30 minutes after extubation(T2). We have defined H0, H1 and H2, the maximum course of the vocal cords measured respectively at T0, T1 and T2
Study: NCT05255640

Intervention type: PROCEDURE
Intervention: operation of ischemia of the lower limbs
Description: The intervention technique is left to the judgment of the investigator to treat the ischemia
Study: NCT06533982

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity interval exercise session
Description: Physical activity session supervised and adapted on ergometer

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric neuromuscular exercise session
Description: Physical activity session supervised and adapted with a handgrip
Study: NCT04914572

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic rainforest mindful walking
Description: A two-kilometer trail curated by the National Parks Board, Singapore. The walk will be led by Mindfulness Practitioner who volunteered to be guides for this study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic rainforest walk
Description: A two-kilometer trail curated by the National Parks Board, Singapore. The walk will be led by volunteer guides recruited by the research team.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Campus Green walk
Description: A two-kilometer trail curated by the Office of Facility Management, NUS. The walk will be led by volunteer guides recruited by the research team.
Study: NCT04635722

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Management Intervention
Description: Participants attend group and individual dietary education sessions. Participants create a diet plan that satisfies their needs. Participants aim to lose 1 pound weekly until a BMI of 25 is reached. Participants are evaluated through daily self-weighing, dietary records, and food frequency questionnaires.
Study: NCT06254521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab combined with chemotherapy
Description: Drug: Oxaliplatin Oxaliplatin 130mg/m2 for chemotherapy on Day 1 every 3 weeks and repeat for 2 or 4 cycles. The dose reduction protocol for oxaliplatin-induced toxicity was implemented according to the report in BJC (2018) 118:1322-1328.~Drug: Capecitabine Oral Capecitabine 1000 mg/m2 twice daily combined with oxaliplatin chemotherapy from Day 1 to Day 14 every 3 weeks and repeat for 2 or 4 cycles. The dose reduction protocol for capecitabine-induced toxicity was implemented according to the report in BJC (2018) 118:1322-1328.~Drug: Anti-PD-1 Monoclonal Antibody 200 mg on Day 1 every 3 weeks and repeat for 2 or 4 cycles. The incidence of adverse events with Anti-PD-1 Monoclonal Antibodies is relatively low. The PD-1 monoclonal antibody (Tislelizumab) dose adjustment was implemented according to the prescribing information.~Other Names:~Tislelizumab~Procedure: Colectomy The specific surgical approach, whether it be laparoscopic
Study: NCT05048771

Intervention type: OTHER
Intervention: Questionnaire
Description: Patients will be surveyed through self-administered questionnaires and semidirected interviews with a psychologist
Study: NCT05336682

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lesion Sterilization and Tissue Repair with radicular instrumentation
Description: Coronal and accessible radicular pulp tissue are extirpated using rotary files. After proper drying, the paste is placed in the cavity and the canals.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lesion Sterilization and Tissue Repair without radicular instrumentation
Description: Only the coronal pulp is removed, the pulpal floor is covered with triple antibiotic paste with propylene glycol mix.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional pulpectomy
Description: Pulp tissue extirpation is done. Biomechanical preparation is done using rotary files with frequent irrigation with Chlorhexidine. The canals are dried using sterile absorbent paper points followed by obturation by the paste of ZOE.
Study: NCT06478784

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: The experimental group (ACTIVE GROUP) will perform a circuit-based muscular strength program at high intensity three days per week for 10 weeks.~Each session will last approximately 45 minutes.~The Resistance training program will be supervised by staff from the Department of Health Sciences and Sports of the Miguel de Cervantes European University of Valladolid and will be carried out at the facilities of the Miguel de Cervantes European University of Valladolid.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low aerobic training
Description: Patients assigned to this group will perform exercise in static bicycle during 45 minutes three days a week, with a duration of 10 weeks.~This second group, despite performing the aerobic exercise, is considered control, since they will perform low-intensity aerobic exercise (50% of the maximum power developed in cycloergometer)~The Resistance training program will be supervised by staff from the Department of Health Sciences and Sports of the Miguel de Cervantes European University of Valladolid and will be carried out at the facilities of the Miguel de Cervantes European University of Valladolid.